Pricing Log in Create free account

Apimeds Pharmaceuticals US, Inc. (APUS) vs Biofrontera Inc. (BFRI)

Apimeds Pharmaceuticals US, Inc. and Biofrontera Inc. are both Drug Manufacturers Specialty & Generic companies. Biofrontera Inc. is the larger, with a market value of $12.6M against $6.6M — 1.9× the size. Apimeds Pharmaceuticals US, Inc. has the higher net margin (0.00% vs −13.8%) and the higher return on invested capital (−16.0% vs −69.5%). Across the 13 metrics below, Apimeds Pharmaceuticals US, Inc. leads on 7 and Biofrontera Inc. on 6.

Valuation

Metric APUS BFRI Drug Manufacturers Specialty & Generic median
P/E n/m n/m 19.25
P/S n/m 0.23 2.11
P/B 0.07 1.78 1.78
Price to free cash flow n/m n/m 16.14
EV/EBITDA n/m n/m 12.58
EV/Sales n/m 0.23 2.73
Earnings yield (905.20%) (54.88%) (4.38%)
Free cash flow yield (192.65%) (74.83%) 0.00%

Profitability

Metric APUS BFRI Drug Manufacturers Specialty & Generic median
Gross margin — 79.25% 53.94%
Operating margin 0.00% (14.22%) 0.00%
Net margin 0.00% (13.78%) 0.00%
Free cash flow margin 0.00% (17.17%) 0.00%
Return on equity (100.13%) (988.35%) (0.40%)
Return on assets (84.20%) (28.80%) (3.32%)
Return on invested capital (15.96%) (69.45%) 0.00%

Growth

Metric APUS BFRI Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) — 17.83% 10.01%
EPS growth (last fiscal year) (205.56%) 67.70% 49.06%
Revenue growth, 5-year CAGR — 17.21% 6.74%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric APUS BFRI Drug Manufacturers Specialty & Generic median
Debt to equity 0.08 0.78 0.05
Current ratio 0.51 1.18 2.31
Net debt to EBITDA 0.38 0.17 0.97

Dividend

Metric APUS BFRI Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.57%
Payout ratio — — 0.27

Size

Metric APUS BFRI Drug Manufacturers Specialty & Generic median
Market cap 6.62m 12.58m 276.90m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack